CCR5 receptor antagonists block metastasis to bone of v-Src oncogene-transformed metastatic prostate cancer cell...

Area of Science:

• Oncology
• Molecular Biology
• Cancer Metastasis

Background:

• Src family kinases (SFK) are crucial for cell signaling in cancer, regulating proliferation and metastasis.
• While Src mutations are rare in prostate cancer, elevated SFK activity is common, suggesting a role in disease progression.
• Understanding the mechanisms of prostate cancer bone metastasis is critical for developing effective therapies.

Purpose of the Study:

• To investigate the molecular mechanisms underlying prostate cancer bone metastasis.
• To identify signaling pathways activated during in vivo tumor growth and metastasis.
• To evaluate the therapeutic potential of targeting identified pathways in prostate cancer.

Main Methods:

• Transduction of murine prostate epithelium with oncogenic v-Src to create a prostate cancer model.
• Analysis of metastatic patterns in FVB mice, specifically to brain and bone.
• Gene expression profiling of tumors grown in vivo versus in tissue culture.
• Assessment of tumor burden reduction using an oral CCR5 antagonist.

Main Results:

• Prostate cancer cell lines engineered with v-Src metastasized to the brain and bone in FVB mice.
• Gene expression profiling revealed activation of a CCR5 signaling module in tumors grown in vivo.
• Administration of a CCR5 antagonist significantly reduced metastatic burden throughout the body, including bone and brain.

Conclusions:

• Activation of the CCR5 signaling pathway is implicated in prostate cancer bone and brain metastasis.
• Targeting CCR5 with antagonists represents a promising therapeutic strategy for advanced prostate cancer.
• Clinical trials of CCR5 inhibitors should be considered for patients with evidence of CCR5 pathway activation in their tumors.